| Sep 9 |
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
|
| Sep 9 |
Top 2 Health Care Stocks That May Collapse This Quarter
|
| Sep 9 |
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
|
| Sep 9 |
Roivant Provides Update on Graves’ Disease Development Program
|
| Sep 9 |
Immunovant Provides Update on Graves’ Disease Development Program
|
| Sep 5 |
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
|
| Sep 5 |
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
|
| Sep 2 |
Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?
|
| Aug 9 |
Q1 2025 Roivant Sciences Ltd Earnings Call
|
| Aug 6 |
Immunovant GAAP EPS of -$0.60 misses by $0.07
|
